Tarsus Appoints Neera Clase as Chief Commercial Officer, Effective November 1

Tarsus Pharmaceuticals Inc. (TARS) named Neera Clase chief commercial officer, effective November 1, 2026, elevating her from interim commercial chief, a role she has held since July. Clase, previously senior vice president of market access, will lead commercial strategy and execution, focused on expanding XDEMVY (lotilaner ophthalmic solution 0.25%), FDA-approved for Demodex blepharitis. She said she believes the drug has peak sales potential exceeding $2 billion. She will also oversee commercial planning for Phase 3 programs Gildeuretinol, an investigational treatment for Stargardt disease, and IRX-101, an investigational ocular antiseptic, plus Phase 2 programs TP-04 for ocular rosacea and TP-05 for Lyme disease prevention. Clase brings more than 25 years of biopharmaceutical experience and has helped commercialize over 10 products, with prior senior commercial and market access roles at Acadia Pharmaceuticals, Relypsa and Abbott Laboratories. TARS closed at $72.05, up 1.82%. Shares were down 0.54% at $71.66 in overnight trading.